To unlock this feature and to subscribe to our weekly evidence emails, please create a FREE orthoEvidence account.

SIGNUP

Already Have an Account?

Loading...
Visit our Evidence-Based Covid-19 Website and Stay Up to Date with the latest Research.
Ace Report Cover

Transmuscular Quadratus Lumborum Block With Pericapsular Injection For Primary Hip Arthroscopy

Share
Reprints
Cite This
About
+ Favorites
Share
Reprints
Cite This
About
+ Favorites
Ace Report Cover
August 2024

Transmuscular Quadratus Lumborum Block With Pericapsular Injection For Primary Hip Arthroscopy

Vol: 306| Issue: 8| Number:25| ISSN#: 2564-2537
Study Type:Therapy
OE Level Evidence:1
Journal Level of Evidence:1

Transmuscular Quadratus Lumborum Block Does Not Provide Significant Benefit for Primary Hip Arthroscopy with Pericapsular Infiltration: A Randomized Control Trial.

Arthroscopy . 2023 Dec;39(12):2456-2463.

Contributing Authors:
UO Umeh DJ Kaplan D Diskina E Commeh G Cuff A Hertling T Youm

Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here

Synopsis

103 patients undergoing hip arthroscopy for femoroacetabulaar impingement were randomized to receive either 30ml of 0.5% bupivacaine in a transmuscular quadratus lumborum block with pericapsular injection (QLB + PCI; n=52) or PCI alone (n-51). The primary outcome of interest was postoperative pain scores assessed via the numerical rating scale (NRS) at 30 minutes postoperatively and immediately pr...

CME Image

Did you know that you’re eligible to earn 0.5 CME credits for reading this report!

LEARN MORE

Join the Conversation

Please Login or Join to leave comments.

Learn about our AI Driven
High Impact Search Feature

High Impact Icon

Our AI driven High Impact metric calculates the impact an article will have by considering both the publishing journal and the content of the article itself. Built using the latest advances in natural language processing, OE High Impact predicts an article’s future number of citations better than impact factor alone.

Continue